Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (NCT06122779)
A Phase 2A, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0002 — Birmingham, Alabama
Age range: 40 Years to 85 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (86 Sites)
Showing the first 25 of 86 sites.
- Local Institution - 0002 — Birmingham, Alabama
- Local Institution - 0096 — Lakewood, Colorado
- Local Institution - 0077 — Jacksonville, Florida
- Local Institution - 0003 — Miami, Florida
- Local Institution - 0099 — Miami, Florida
- Local Institution - 0004 — Chicago, Illinois
- Local Institution - 0005 — Hazel Crest, Illinois
- Local Institution - 0029 — Indianapolis, Indiana
- Local Institution - 0028 — St Louis, Missouri
- Local Institution - 0117 — Hackensack, New Jersey
- Local Institution - 0070 — Albany, New York
- Local Institution - 0105 — Brooklyn, New York
- Local Institution - 0008 — New York, New York
- Local Institution - 0059 — Rochester, New York
- Local Institution - 0076 — Rochester, New York
- Local Institution - 0094 — Rosedale, New York
- Local Institution - 0095 — Durham, North Carolina
- Local Institution - 0016 — Oklahoma City, Oklahoma
- Local Institution - 0078 — Abington, Pennsylvania
- Local Institution - 0001 — Tullahoma, Tennessee
- Local Institution - 0104 — Austin, Texas
- Local Institution - 0036 — Dallas, Texas
- Local Institution - 0015 — Houston, Texas
- Local Institution - 0054 — Ciudad del Libertador General San Martin, Buenos Aires
- Local Institution - 0115 — Zárate, Buenos Aires
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Heart Failure
- REDUCE LAP-HFREF TRIAL — New York, New York
- Physiological Effects Ketone Ester in Heart — Cleveland, Ohio
- DASH Diet in Heart Failure Outpatients — Sacramento, California
- Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients — Huntsville, Alabama
- LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. — Birmingham, Alabama
- A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation — Alexander City, Alabama
Explore by condition: All Heart Failure clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.